… Two antifibrotic therapies have been approved for the treatment of IPF: nintedanib and …
IPF and the utility of antifibrotic therapies, with a focus on the importance of early treatment. …

… Two antifibrotic medications (nintedanib and pirfenidone) were recommended (conditionally)
for the treatment of patients with idiopathic pulmonary fibrosis (IPF) in the 2015 IPF …

… that differences in the dose, duration, or mode of steroid therapy between the untreated
and antifibrotic therapy groups could explain some of the observed differences in survival. …

… therapy, alternative approaches to the treatment of IPF are being pursued. The following
is a brief discussion of antifibrotic therapy and other promising agents in the treatment of IPF. …

… The assumption behind such restricted criteria, which are adopted for most IPF clinical
trials, is mainly that advanced disease is less likely to be amenable to any anti-fibrotic therapy, …

Idiopathic pulmonary fibrosis (IPF) is a lethal form of idiopathic diffuse lung disorders for which
no current treatment is effective. The aim of the present study was to systematically review …

… idiopathic pulmonary fibrosis (IPF), namely increasing age, male sex, and comorbidities such
as hypertension and diabetes. However, the role of antifibrotic therapy … potential antifibrotic …

… is essential for treatment decisions in patients with idiopathic pulmonary fibrosis (IPF). This
review aimed to evaluate the prognosis of patients with IPF without anti-fibrotic therapy. We …

… initial treatment of idiopathic pulmonary fibrosis, yet a retrospective study of 127 patients
with cryptogenic fibrosing alveolitis published in 1980 showed that only 17% had an objective …

… Studies were included if they were original articles comparing mortality or AE events in
IPF patients with and without antifibrotic treatment. Relative risk (RR) with 95%CI was pooled …